Investors
Corporate Profile
Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs.
Ocugen News
June 21, 2022 Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
June 14, 2022 Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
June 13, 2022 Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
Corporate Presentation
Events
2022 BIO International Convention June 13, 2022 at 4:45 PM PDT
H.C. Wainwright Global Investment Conference May 24, 2022 at 1:30 PM EDT